Effects of Psilocybin in Post-Treatment Lyme Disease

Post-Treatment Lyme Disease Clinical Trial

Official title: Effects of Psilocybin in Post-Treatment Lyme Disease

Status Enrolling by invitation

Clinical Trial Summary

This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).

Clinical Trial Description

This pilot study will evaluate the therapeutic potential of psilocybin in people with well-documented current Post-Treatment Lyme Disease (PTLD). Study measures will assess the impact of psilocybin-assisted treatment on overall symptom burden and quality of life in 20 people with PTLD. This is an open-label proof-of-concept trial in which participants will complete an 8-week course of study treatment including two psilocybin sessions (15mg in week 4 and 15 or 25mg in week 6) with psychological support, and follow-up assessments 1, 3, and 6 months after the final psilocybin session. ;

Related Conditions & MeSH terms

• Lyme Disease
• Lyme Disease, Chronic
• Post-Treatment Lyme Disease

• NCT number: NCT05305105
• Study type: Interventional
• Source: Johns Hopkins University
• Status: Enrolling by invitation
• Phase: Phase 1
• Start date: July 1, 2022
• Completion date: December 31, 2024